The most typical side effect of Inspra (Eplerenone) is hyperkalemia, which requires management through regular monitoring and medication adjustments. The following provides a comprehensive analysis of its adverse effect profile and strategies for addressing hyperkalemia, covering risk factors, clinical manifestations, and intervention measures.

1. Hypokalemia-related side effects

(1) Incidence and Mechanism: Eplerenone reduces potassium excretion by inhibiting the aldosterone receptor, with approximately 5-10% of patients developing serum potassium levels >5.5 mEq/L, and the risk is higher in patients with renal insufficiency.

(2) Clinical manifestations: Early symptoms include numbness in the hands and feet, muscle weakness, and in severe cases, may lead to arrhythmia or even cardiac arrest, requiring immediate medical attention.

2. Other Common Side Effects

(1) Metabolic abnormalities: May lead to elevated blood cholesterol and triglyceride levels, requiring regular lipid monitoring.

(2) Digestive system: Diarrhea and loss of appetite are relatively common, typically mild and self-limiting.

(3) Endocrine effects: Both males and females may experience breast tenderness, while females occasionally report abnormal vaginal bleeding.

3. Strategies for Managing Hyperkalemia

(1) Precautions: Assess renal function before medication; withhold administration if baseline potassium levels exceed 5.0 mEq/L; avoid concurrent use with potassium-sparing diuretics or potassium supplements.

(2) Monitoring requirements: Measure serum potassium every 1-2 weeks during initial treatment, and perform monthly follow-ups after stabilization; increase monitoring frequency for elderly patients or those with renal insufficiency.

(3) Emergency management: If serum potassium exceeds 5.5 mEq/L, reduce the dosage or discontinue the medication; if it surpasses 6.0 mEq/L, administer intravenous calcium and insulin for potassium-lowering therapy.

4. Special Populations Precautions

(1) Renal insufficiency: For patients with a creatinine clearance <50 mL/min, the initial dose should be halved, and electrolytes should be closely monitored.

(2) Elderly patients: Age-related decline in renal function may increase the risk of hyperkalemia; treatment should start at 25mg/day.